Scribe Therapeutics (NASDAQ:SCTX) Stock Price Down 5.7% – Should You Sell?

Posted by Stanley Muller on Sep 6th, 2026

Shares of Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) were down 5.7% on Friday . The stock traded as low as $29.05 and last traded at $29.05. 76,183 shares changed hands during trading, a decline of 66% from the average session volume of 224,100 shares. The stock had previously closed at $30.81.

Key Scribe Therapeutics News

Here are the key news stories impacting Scribe Therapeutics this week:

Positive Sentiment: HC Wainwright reduced its projected FY2026 loss to $3.68 per share from $6.72 and its FY2027 loss to $2.52 per share from $4.90. Quarterly estimates were also improved, including Q3 2026 EPS of $(0.42), Q4 2026 EPS of $(0.40), and 2027 quarterly losses ranging from $(0.47) to $(0.82). These revisions indicate expectations for improving operating performance. MarketBeat SCTX analyst estimates
Positive Sentiment: The $60 target implies substantial upside from the stock’s recent trading level, potentially supporting investor sentiment if other analysts or upcoming results confirm the improved earnings trajectory. MarketBeat SCTX analyst coverage
Neutral Sentiment: An AAII article examines whether SCTX is a good investment, but the supplied headline does not provide a specific recommendation or new company announcement. Is Scribe Therapeutics Inc. Stock a Good Investment?
Negative Sentiment: Scribe remains unprofitable, with analysts expecting a full-year loss and the company’s latest reported quarter showing a loss despite beating EPS expectations. Revenue was below consensus estimates, which may be weighing on the stock and offsets some of the optimism from the revised forecasts.

Analysts Set New Price Targets

Several research firms recently issued reports on SCTX. Wall Street Zen upgraded shares of Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st. HC Wainwright initiated coverage on shares of Scribe Therapeutics in a report on Monday, August 31st. They issued a “buy” rating and a $60.00 target price on the stock. Leerink Partners started coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target for the company. Wells Fargo & Company began coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 price target for the company. Finally, Guggenheim initiated coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $50.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.75.

Check Out Our Latest Stock Analysis on SCTX

Scribe Therapeutics Price Performance

Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last posted its earnings results on Wednesday, September 2nd. The company reported ($3.84) EPS for the quarter, beating analysts’ consensus estimates of ($6.20) by $2.36. The company had revenue of $1.92 million during the quarter, compared to analyst estimates of $3.10 million. Analysts anticipate that Scribe Therapeutics Inc. will post -3.68 EPS for the current year.

Insider Activity at Scribe Therapeutics

In related news, Director Behzad Aghazadeh acquired 7,905 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was purchased at an average price of $18.25 per share, with a total value of $144,266.25. Following the transaction, the director owned 3,088,888 shares of the company’s stock, valued at approximately $56,372,206. This trade represents a 0.26% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Carl L. Gordon bought 1,000,000 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was bought at an average price of $15.00 per share, with a total value of $15,000,000.00. Following the acquisition, the director directly owned 1,348,825 shares in the company, valued at $20,232,375. The trade was a 286.68% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 3,727,237 shares of company stock valued at $56,291,746 over the last 90 days.

About Scribe Therapeutics

(Get Free Report)

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.